# Association between Long-Term Change in Arterial Stiffness and Cardiovascular Outcomes in Kidney Transplant Recipients

Madonna Salib, Arnaud Simon, Nicolas Girerd, Anna Kearney-Schwartz, Patrick Rossignol, Athanase Benetos, Luc Frimat, Sophie Girerd

<figure><img src="image_1.png" /></figure>

## To cite this version:

Madonna Salib, Arnaud Simon, Nicolas Girerd, Anna Kearney-Schwartz, Patrick Rossignol, et al. "Association between Long-Term Change in Arterial Stiffness and Cardiovascular Outcomes in Kidney Transplant Recipients: Insights from the TRANSARTE Study." Journal of Clinical Medicine, 2022, 11 (5), pp.1410. 10.3390/jcm11051410. [hal-03605701](https://hal-univ-lorraine.fr/hal-03605701)

HAL Id: hal-03605701

https://hal.univ-lorraine.fr/hal-03605701

Submitted on 11 Mar 2022

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_2.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
2
3
4
# Association between long-term change in arterial stiffness and cardiovascular outcomes in kidney transplant recipients: Insights from the TRANSARTE study

Madonna Salib¹,†, Arnaud Simon²,†, Nicolas Girerd¹, Anna Kearney-Schwartz³, Patrick Rossignol¹,

Athanase Benetos³, Luc Frimat², Sophie Girerd¹,²,*

7

8 ¹ Université de Lorraine, Inserm, Centre d'Investigations Cliniques- 1433, and Inserm U1116; CHRU Nancy; F-CRIN INI-CRCT, Nancy, France ;

9 m.salib@chru-nancy.fr (M.S.); n.girerd@chru-nancy.fr (N.G.); p.rossignol@chru-nancy.fr (P.R.)

10 2 Nephrology Department, University Hospital of Nancy, Vandoeuvre les Nancy, France; a.simon@chru-nancy.fr (A.S.); l.frimat@chru-nancy.fr

11 (L.F.)

12 3 Université de Lorraine, Inserm, DCAC, Nancy, France; Department of Geriatrics and Federation Hospital-University on Cardiovascular Aging

13 (FHU-CARTAGE), University Hospital of Nancy, Université de Lorraine, Nancy, France; a.kearney-schwartz@chru-nancy.fr (A.K-S);

14 a.benetos@chru-nancy.fr (A.B.)

15

16 † Theses authors contributed equally to this work

17

18 *Correspondence: s.girerd@chru-nancy.fr

19

**Abstract:** (1) Background: Increased arterial stiffness is associated with cardiovascular (CV) diseases in end-stage renal disease patients and CV mortality remains higher in kidney transplantation (KT) recipients compared to general population. KT is associated with an improvement of arterial stiffness in the early post-transplant period, followed by a potential reworsening in the late period. In a cohort of KT patients, we evaluated the associations of pulse wave velocity (PWV) measured at different time-points (pre-transplant, early and late pos t-transplant periods) with CV morbi-mortality, as well as the evolution between these measurements with the CV morbi-mortality. (2) Methods: 40 KT recipients with a 10-year follow-up were included. The association of PWV with CV events was assessed with multivariable cox analysis. Backward linear regressions were conducted to identify the determinants of PWV at 1-year and those of the long-term evolution of PWV after KT (delta PWV at 1 year – latest PWV). (3) Results: The absence of arterial stiffening during long-term follow-up after KT is associated with a lower CV outcomes rate [(HR for the delta PWV = 0.76 (0.58-0.98), p=0.036]. Age at KT is associated with the worsening of arterial stiffness in the late post-transplantation period [β for the delta PWV = -0.104, p=0.031]. A high PWV at one year was associated with a potential for recovery during follow-up [β = 0.744, p<0.0001]. (4) Conclusion: The absence of PWV worsening in the late post-transplantation period was significantly associated with a lower risk of CV events whereas early changes in PWV were not. Finding an intervention able to reduce long-term PWV could improve the prognosis of KT recipients.

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

**Keywords:** arterial stiffness, cardiovascular diseases, kidney transplantation, pulse-wave velocity

36

1. Introduction

37

38

39

40

41

Cardiovascular (CV) diseases are the leading cause of death in patients in end-stage renal disease (ESRD). After kidney transplantation (KT) and the restoration of renal function, the risk of CV mortality remains high compared with the general population [1]. Increased PWV, a marker of arterial stiffness, has been reported to be a strong risk factor of CV morbi-mortality in ESRD [2]. In KT, some studies also reported this association [3, 4].

42

43

44

45

46

The mechanisms underlying arterial stiffness in KT are numerous, involving the pretransplant history of patients (duration of ESRD or dialysis, and co-morbidities such as hypertension or diabetes). Age also remains a key determinant of PWV in KT [5]. Nevertheless, data on the evolution of PWV suggest a decrease in PWV during the first year after transplantation [6, 7] followed by an increase in PWV after that point [1]. This long-term deterioration of PWV may indicate that factors
47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

arising with transplantation, e.g. immunosuppressive drugs could have a detrimental impact on PWV [8]. It was also reported that that donor age was as an independent factor for PWV in KT with a deceased donor [9]."

Therefore, considering the potential improvement of arterial stiffness in the early post-transplantation period [6, 7], and the potential reworsening in the late-transplantation period [1], we aimed to evaluate the associations between CV morbi-mortality and PWV measured at different time-points (pre-transplantation, early post-transplantation, and late post-transplantation periods), as well as the evolution between these measurements with the CV morbi-mortality, in a cohort of kidney transplant patients. In this framework, we investigated the association of arterial stiffness with CV events in KT recipients from the monocentric TRANSARTE study (Transplantation and Arteries).

## 2. Materials and Methods

### 2.1. Study population

A detailed description of the TRANSARTE study have been published previously [7]. Briefly, 100 ESRD patients were recruited from the waiting list of the University Hospital of Nancy to characterize the evolution of arterial stiffness after KT in a population of ESRD patients. Among the kidney-transplanted patients, the present study was carried out on 40 renal transplant recipients with available predefined PWV measurements, as previously described [7]. The composite primary outcome of the study is CV event (defined by acute coronary syndrome, myocardial infarction, angioplasty, vascular angioplasty, coronary bypass, ischemic or hemorrhagic stroke, angioplasty of lower extremity arteries, amputation, and atrial fibrillation).

### 2.2. Measurement of PWV

PWV measurements were performed using the Complior® technique (ALAM medical), which simultaneously records arterial pulse waves at carotid and femoral sites. Propagation time (t) of the incident wave was measured through mechanotransducer probes, carotid-femoral distance (D) was evaluated with a tape measure, and PWV (m/s) was obtained by the formula PWV=D*0.8/(t).

### 2.3. Statistical Analysis

Analyses were performed using R version 4.0.2 (R Development Core Team, Vienna, Austria). Means are presented with SD and median with 25th and 75th percentiles. P-values are considered significant if < 0.05. Association of PWV with CV events was assessed using Cox models. Backward linear regression was performed to identify the determinants of PWV at 1-year and absolute changes in PWV post-transplantation (delta between PWV before transplantation and at 1-year, and between 1- and 4-years post-transplantation). Gender, age at transplantation, mean arterial blood pressure (MBP), hypercholesterolemia, diabetes mellitus, smoking, history of angina or myocardial infarction, previous strokes, CNI (Tacrolimus/Cyclosporine) and cause of ESRD were considered as independent variables. In addition, PWV at one-year post-transplantation was considered in the model focusing on late change in PWV. All variables with a p <0.15 in univariable analysis were used as candidate variables in the multivariable model prior to backward selection procedures.

## 3. Results

### 3.1. Baseline characteristics of patients

In the 40 patients receiving either a living (n=6) or a deceased (n=34) donor allograft, the median age at transplantation (years) was 53 [47-60]. 19 (47.5%) were female. Of the subjects, 5 (12.5%) were diabetic, 2 (5.0%) had history of angina or myocardial infarction and 2 (5.0%) had previous strokes. The mean pre-transplantation, 1-year post-transplantation and latest post-transplantation PWVs (m/s) (respectively measured at a median delay of 7 [2-11] months before KT, 13 [11-25] months after KT, and 52 [37-62] months after KT) were 8.9 +/- 2.45, 9.0 +/- 2.8 and 8.9 +/- 2.4 (m/s), respectively (p=0.96). The majority of patients received calcineurin inhibitors (CNI) (95%), most of them cyclosporine (55.3%). During the median follow-up period of 10.9 years, 12 patients died, 11 patients had a CV event and 6 patients returned in dialysis (Table 1).
<table><caption>**Table 1.** Baseline characteristics and outcomes of patients</caption><thead><tr><th></th><th>Overall population<br>N=40</th></tr></thead><tbody><tr><td>Baseline characteristics</td><td></td></tr><tr><td>Female (%)</td><td>19 (47.5)</td></tr><tr><td>Age at transplantation (years)</td><td>53 [47-60]</td></tr><tr><td>Medical history</td><td></td></tr><tr><td>Hypercholesterolemia (%)</td><td>20 (50.0)</td></tr><tr><td>Smoking (%)</td><td>16 (40.0)</td></tr><tr><td>Diabetes (%)</td><td>5 (12.5)</td></tr><tr><td>History of angina or myocardial infarction (%)</td><td>2 (5.0)</td></tr><tr><td>Previous Strokes (%)</td><td>2 (5.0)</td></tr><tr><td>Cause of ESRD (%)</td><td></td></tr><tr><td>Diabetes</td><td>2 (5.0)</td></tr><tr><td>Glomerulopathy</td><td>7 (17.5)</td></tr><tr><td>Malformation</td><td>8 (20.0)</td></tr><tr><td>Polycystic kidney disease</td><td>10 (25.0)</td></tr><tr><td>Vascular</td><td>6 (15.0)</td></tr><tr><td>Other</td><td>7 (17.5)</td></tr><tr><td>Pre-transplantation dialysis (%)</td><td>30 (75.0)</td></tr><tr><td>Hemodialysis (%)</td><td>23 (76.7)</td></tr><tr><td>Peritoneal dialysis (%)</td><td>7 (23.3)</td></tr><tr><td>Dialysis duration (years)</td><td>2.7 [2.1-3.5]</td></tr><tr><td>Transplantation characteristics</td><td></td></tr><tr><td>Calcineurin inhibitors (%)</td><td>38 (95.0)</td></tr><tr><td>Cyclosporine (%)</td><td>21 (55.3)</td></tr><tr><td>Tacrolimus (%)</td><td>17 (44.7)</td></tr><tr><td>Donor type</td><td></td></tr><tr><td>Living donor (%)</td><td>6 (15.0)</td></tr><tr><td>Deceased donor (%)</td><td>34 (85.0)</td></tr><tr><td>Standard criteria donors (SCD)</td><td>17 (51.5)</td></tr><tr><td>Expanded-criteria donors (ECD)</td><td>16 (48.5)</td></tr><tr><td>Arterial stiffness characteristics</td><td></td></tr><tr><td>Duration between pre-transplantation PWV and transplantation (months)</td><td>7 [2-11]</td></tr><tr><td>Pre-transplantation PWV (m/s)</td><td>8.9 ± 2.5</td></tr><tr><td>Pre-transplantation mean arterial blood pressure (mmHg)</td><td>101 ± 14</td></tr><tr><td>Duration between transplantation and 1-year post-transplantation PWV (months)</td><td>13 [11-25]</td></tr><tr><td>1-year post-transplantation PWV (m/s)</td><td>9.0 ± 2.8</td></tr><tr><td>1-year post-transplantation mean arterial blood pressure (mmHg)</td><td>94 ± 12</td></tr></tbody></table>
<table><tr><td>Duration between transplantation and the latest post-transplantation PWV (months)</td><td>52 [37-62]</td></tr><tr><td>The latest post-transplantation PWV (m/s)</td><td>8.9 ± 2.4</td></tr><tr><td>The latest post-transplantation mean arterial blood pressure (mmHg)</td><td>91 ± 12</td></tr><tr><td>Post-transplantation characteristics</td><td></td></tr><tr><td>eGFR at one year</td><td>48.5 [40.5-54.3]</td></tr><tr><td>eGFR at the last contact</td><td></td></tr><tr><td>All patients</td><td>48.0 [25.8-53.8]</td></tr><tr><td>Not back to dialysis patients</td><td>48.5 [42.3-56.8]</td></tr><tr><td>Follow-up time (years)</td><td>10.9 [8.2-12.0]</td></tr><tr><td>Back to dialysis or preemptive retransplantation (%)</td><td>6 (15.0)</td></tr><tr><td>Death (%)</td><td>12 (30.0)</td></tr><tr><td>CV events post-transplantation (%)</td><td>11 (27.5)</td></tr></table>

Data presented as mean ± standard deviation; number (percent); and median [interquartile range].

Abbreviations: ESRD, end-stage renal disease; PWV; pulse wave velocity; eGFR; estimated glomerular filtration rate; CV, cardiovascular.

CV events post-transplantation, the composite primary outcome of the study, is defined by acute coronary syndrome, myocardial infarction, angioplasty, vascular angioplasty, coronary bypass, ischemic or hemorrhagic stroke, angioplasty of lower extremity arteries, amputation, and atrial fibrillation.

## 3.2. Association of PWV with CV events

In multivariable analysis adjusted for PWV post-transplantation at 1-year and age at transplantation, the absence of arterial worsening in the late post-transplantation period was significantly associated with a lower risk of CV events [(HR for the delta PWV at 1 year – latest PWV = 0.76 (0.58-0.98)]. On the contrary, the evolution of PWV between the pre-transplant period and the early post-transplantation period, as well as the PWV at 1 year, was not significantly associated with CV mortality (Figure 1). The complete output of the Cox models is provided in Supplementary Table S1.

## 3.3. Determinants of PWV using backward linear regression

The backward multivariate regression analyses identified age at KT and diabetes were significantly associated with an increased arterial stiffness at 1-year post-transplantation (β=0.013, p=0.006 and β=0.509, p<0.0001, respectively). Age at KT was also associated with the worsening of arterial stiffness in the late post-transplantation period, even after adjusting for PWV at 1-year [β for the delta (PWV at 1 year – PWV at 4 years = -0.104, p=0.031]. A higher PWV at 1-year was associated with PWV decrease over the late post-transplantation period [β=0.744, p<0.0001] (Figure 1). Importantly, MBP was not retained as a significant factor in the selection process. A detailed description of the backward regression model is provided in Supplementary Table S2.
Panel A

<figure><img src="image_3.png" /></figure>

*p-value <0.05;
All models were adjusted for age at transplantation;
PWV change was adjusted for the baseline PWV on top of age at transplantation

Panel B

<figure><img src="image_4.png" /></figure>

Age at transplantation: PWV at 1-year was put into the model of late change in PWV as independent variable.

*PWV at 1-year post-transplantation was used alone in the model.

<caption>**Figure 1.** (a) Forest plot of the association between pulse wave velocity (PWV) and cardiovascular (CV) events; (b) the determinants of PWV using backward linear regression.</caption>
123

124

125

126

127

128

129

130

Despite the improvement of renal function conferred by KT, CV mortality remains higher in KT recipients compared with the general population. In KT, some studies demonstrated that an increased arterial stiffness was associated with CV mortality [3, 4]. Nevertheless, the evolution of arterial stiffness is complex after KT; some studies reported an early improvement [5, 6], and others reported a long-term reworsening [1]. Vascular remodeling is complex and involves alterations of extracellular matrix by uremic toxins which are not fully reversed by KT [6]. Moreover, immunosuppressive therapy is associated with hypertension, diabetes or dyslipidemia and may indirectly or directly impact the vascular system.

131

132

133

134

135

The present study focuses on the association between CV morbi-mortality and the PWV measured at different time-point, as well as the evolution of the PWV through time. Of note, despite the low number of patients, we had for the first time the opportunity to measure the arterial stiffness in the pre-KT, the early post KT, and the late post KT periods. Moreover, we analyzed CV outcomes after a ten-year follow-up period.

136

137

138

139

140

141

In a study on 220 kidney transplant recipients, carotid-femoral PWV evaluated at 3 and 12 months after KT was significantly associated with morbi-mortality 5.5 years after KT, whereas delta of PWV between month-12 and month-3 was not [8]. However, the present study added that an increased PWV between month-12 and month-48 is associated with CV events (adjusted for PWV at 1-year after KT and age at KT) in kidney recipients 10 years after KT. This suggests the impact of non-traditional factors in the late post KT period, probably related to immunosuppressive therapy.

142

143

144

145

146

Unsurprisingly, age is associated with increased PWV at one year, but also with less improvement in the long-term post-transplantation period. Ignace et al. previously reported that older patients had a higher improvement of PWV in the early post-transplantation period at 3 months post KT [9]. We can hypothesize that despite this early improvement, arteries from older patients are more prone to deterioration related to immunosuppressive regimens after a long-term exposition.

147

148

149

150

151

On the contrary, increased PWV at one year is associated with increased potential improvement in the long-term post-transplantation period. One can hypothesize that arterial stiffness mainly related to CKD but not age has a greater potential of recovery after KT, and that the susceptibility of the vascular system to immunosuppressive therapy is less pronounced among the youngest patients with ESRD.

152

153

154

155

156

157

It is worth mentioning that, similarly to the results of Kolonko et al. [10], history of diabetes mellitus was a significant determinant of PWV 1-year after transplantation in the present study. Of note, diabetes mellitus was not related to the worsening of PWV change post transplantation, suggesting the stability of PWV in diabetic patients after 1-year of KT. Indeed, it was evident that patients with greater age, diabetes mellitus and higher PWV at baseline had an increased PWV at 1-year after transplantation [11, 12].

158

## 5. Limitations

159

160

161

162

163

164

This study is a single-center study with a small sample size. This prevented the use of more advance statistical analysis such as splines to determine the most adequate prognostic PWV thresholds or the addition of some possibly important covariates in the multivariable analysis. However, we assessed ESRD-related arterial stiffness over a long period of time in a peculiar population of kidney transplanted patients, something that has not been reported previously. Further long-term studies should be conducted better ascertain the long-term changes in PWV following KT.

165

166

There was no preemptive KT in this cohort. Therefore, it was not possible to include the residual renal function before KT to assess its potential impact on the evolution of arterial stiffness after KT.

167

## 6. Conclusions
168

169

170

In this analysis, the absence of pulse wave velocity (PWV) worsening in the late post-transplantation period was significantly associated with a lower risk of CV events. In contrast, the change of PWV observed early during the post transplantation period was not associated with CV events.

171

172

173

In summary, the present study suggests that the worsening of aortic stiffness in the late post KT period has a negative impact on the long-term CV morbi-mortality. Ultimately, finding an intervention able to reduce PWV could improve the prognosis of KT recipients.

174

175

176

**Supplementary Materials:** The following are available online, Table S1: Association of pulse wave velocity (PWV) with CV events; Table S2: Determinants of absolute changes in pulse wave velocity (PWV) post-transplantation (PWV at 1-year – latest PWV) using backward linear regression.

177

178

179

**Author Contributions:** Conceptualization, S.G. and N.G.; Methodology, S.G., N.G., and M.S; Formal Analysis, M.S.; Writing – Original Draft Preparation, M.S. and A.S.; Writing – Review & Editing, all coauthors; Supervision, S.G., N.G., and P.R. All authors have read and agreed to the published version of the manuscript.

180

181

182

**Funding:** This research is part of IMPROVE-PD project which has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 812699.

183

184

**Institutional Review Board Statement:** Approval for the study was obtained from the local research ethics committee.

185

**Informed Consent Statement:** Informed consent was obtained from all subjects involved in the study.

186

187

**Data Availability Statement:** The data presented in this study can be made available upon reasonable request to the corresponding author.

188

**Conflicts of Interest:** The authors declare no conflict of interest.

189

## References

190

1. Desjardins MP, Sidibe A, Fortier C, Mac-Way F, De Serres S, Lariviere R, Spronck B, Goupil R and Agharazii M. Impact of kidney transplantation on aortic stiffness and aortic stiffness index beta0. J Hypertens. 2019; 37:1521-1528.

191

2. Boutouyrie P, Fliser D, Goldsmith D, Covic A, Wiecek A, Ortiz A, Martinez-Castelao A, Lindholm B, Massy ZA, Suleymanlar G, Sicari R, Gargani L, Parati G, Mallamaci F, Zoccali C and London GM. Assessment of arterial stiffness for clinical and epidemiological studies: methodological considerations for validation and entry into the European Renal and Cardiovascular Medicine registry. Nephrol Dial Transplant. 2014; 29:232-9.

192

3. Claes KJ, Heye S, Bammens B, Kuypers DR, Meijers B, Naesens M, Vanrenterghem Y and Evenepoel P. Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients. Transpl Int. 2013; 26:973-81.

193

4. Dahle DO, Eide IA, Asberg A, Leivestad T, Holdaas H, Jenssen TG, Fagerland MW, Pihlstrom H, Mjoen G and Hartmann A. Aortic Stiffness in a Mortality Risk Calculator for Kidney Transplant Recipients. Transplantation. 2015; 99:1730-7.

194

5. Ignace S, Utescu MS, De Serres SA, Marquis K, Gaudreault-Tremblay MM, Lariviere R, Cote I, Houde I, Lebel M and Agharazii M. Age-related and blood pressure-independent reduction in aortic stiffness after kidney transplantation. J Hypertens. 2011; 29:130-6.

195

196

6. Kim HS, Seung J, Lee JH, Chung BH and Yang CW. Clinical Significance of Pre-Transplant Arterial Stiffness and the Impact of Kidney Transplantation on Arterial Stiffness. PLoS One. 2015;10: e0139138.

197

7. Sidibe A, Fortier C, Desjardins MP, Zomahoun HTV, Boutin A, Mac-Way F, De Serres S and Agharazii M. Reduction of Arterial Stiffness After Kidney Transplantation: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2017;6.

198

8. Melilli E, Manonelles A, Montero N, Grinyo J, Martinez-Castelao A, Bestard O and Cruzado J. Impact of immunosuppressive therapy on arterial stiffness in kidney transplantation: are all treatments the same? Clin Kidney J. 2018; 11:413-421.

199

9. Karras A, Boutouyrie P, Briet M, Bozec E, Haymann JP, Legendre C, McMahon LP and Delahousse M. Reversal of Arterial Stiffness and Maladaptative Arterial Remodeling After Kidney Transplantation. Journal of the American Heart Association. 2017;6.

200

201

202

10. Bachelet-Rousseau C, Kearney-Schwartz A, Frimat L, Fay R, Kessler M and Benetos A. Evolution of arterial stiffness after kidney transplantation. Nephrol Dial Transplant. 2011; 26:3386-91.

203

11. Cheddani L, Radulescu C, Chaignon M, Karras A, Neuzillet Y, Duong JP, Tabibzadeh N, Letavernier E, Delahousse M and Haymann JP. From arterial stiffness to kidney graft microvasculature: Mortality and graft survival within a cohort of 220 kidney transplant recipients. PLoS One. 2018;13: e0195928.

204

205

206

12. Kolonko A, Chudek J, Szotowska M, Kuczera P and Wiecek A. Cardiovascular Risk Factors and Markers of Atherosclerosis in Stable Kidney Transplant Recipients. Transplant Proc. 2016; 48:1543-50.

207
219 13. Birdwell KA, Jaffe G, Bian A, Wu P and Ikizler TA. Assessment of arterial stiffness using pulse wave velocity in tacrolimus users the first year post kidney transplantation: a prospective cohort study. BMC Nephrol. 2015; 16:93.

221 14. Korogiannou M, Xagas E, Marinaki S, Sarafidis P and Boletis JN. Arterial Stiffness in Patients With Renal Transplantation; Associations With Co-morbid Conditions, Evolution, and Prognostic Importance for Cardiovascular and Renal Outcomes.

223 Front Cardiovasc Med. 2019; 6:67.